What are the approved indications for rivaroxaban (Rivaban)?

Rivaroxaban (Rivaban) Approved Indications

Rivaroxaban is approved for multiple thromboembolic indications including VTE prevention after orthopedic surgery, treatment of DVT/PE, stroke prevention in nonvalvular atrial fibrillation, and reduction of cardiovascular events in coronary/peripheral artery disease. 1, 2

FDA-Approved Indications

Venous Thromboembolism (VTE) Prevention and Treatment

• Prophylaxis after major orthopedic surgery: Rivaroxaban 10 mg once daily is approved for preventing VTE in patients undergoing total hip or knee replacement surgery 3, 1

  • Treatment should start 6-10 hours post-surgery 3
  • Duration: 2 weeks for total knee replacement, up to 5 weeks for total hip replacement 3, 1

• Treatment of acute DVT and PE: Rivaroxaban is approved for treating acute deep vein thrombosis and pulmonary embolism 3, 2

  • Dosing regimen: 15 mg twice daily for 3 weeks, followed by 20 mg once daily 3
  • The EINSTEIN trials demonstrated non-inferiority to standard enoxaparin/warfarin therapy 3, 1

• Secondary prevention of recurrent VTE: Rivaroxaban 20 mg once daily is approved for reducing risk of recurrent DVT/PE after completing initial anticoagulation 3, 2

  • Superior efficacy over placebo in preventing recurrent venous thromboembolic events 3

Stroke Prevention in Atrial Fibrillation

• Nonvalvular atrial fibrillation: Rivaroxaban is approved to reduce stroke and systemic embolism risk in patients with nonvalvular AF and additional risk factors 3, 2
  • Standard dose: 20 mg once daily with the evening meal 3
  • Dose adjustment: 15 mg once daily for creatinine clearance 30-49 mL/min 3, 1
  • The ROCKET-AF trial showed non-inferiority to warfarin with fewer intracranial and fatal bleeding events 3

Cardiovascular Risk Reduction

• Chronic coronary artery disease or peripheral artery disease: Rivaroxaban is approved for reducing major cardiovascular events in patients with chronic CAD or PAD 2
  • Lower dose regimen (2.5 mg twice daily) combined with antiplatelet therapy 3

Prophylaxis in Acutely Ill Medical Patients

• VTE prophylaxis in hospitalized medical patients: Rivaroxaban is approved for preventing VTE in acutely ill medical patients at risk for thromboembolic complications who are not at high bleeding risk 2

Critical Contraindications and Precautions

Renal Impairment Restrictions

• Severe renal failure (CrCl <30 mL/min): Rivaroxaban is contraindicated or not approved for VTE indications in this population 3, 1
• Moderate renal impairment (CrCl 30-50 mL/min): Use with caution; dose adjustment required for AF indication 3, 1

Other Contraindications

• Hepatic disease with coagulopathy: Not approved for use 3
• Pregnancy and breastfeeding: Contraindicated due to reproductive toxicity and drug passage through placenta and breast milk 3
• Concomitant strong dual inhibitors: Avoid systemic azole-antimycotics or HIV protease inhibitors (strong CYP3A4 and P-glycoprotein inhibitors) 3
• Children and adolescents <18 years: Not approved due to absence of clinical data 3

Important Clinical Considerations

Monitoring

• No routine coagulation monitoring required: Neither PT nor aPTT should be used to monitor rivaroxaban's anticoagulant effect 3, 1
• Renal function assessment: Kidney function should be assessed prior to and during therapy to ensure consistency with dosing requirements 2

Special Populations

• Elderly patients (>75 years): Use with caution due to prolonged half-life (11-13 hours vs. 5-9 hours in younger patients) 3, 1
• Extreme body weights (<50 kg or >120 kg): These patients were underrepresented in trials; consider plasma level assessment if treatment is initiated 3

Bleeding Risk

• Major bleeding rates: 0.1-0.7% in orthopedic surgery trials, comparable to enoxaparin 3
• Intracranial bleeding: Lower rates compared to warfarin in AF trials 3
• No specific antidote was available during initial trials: Management of major bleeding remains empirical, though reversal agents have since been developed 3